- Home
- FLNC vs NVAX Comparison
FLNC vs NVAX Comparison
Compare FLNC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- NVAX
- Stock Information
- Founded
- FLNC 2018
- NVAX 1987
- Country
- FLNC United States
- NVAX United States
- Employees
- FLNC N/A
- NVAX N/A
- Industry
- FLNC Industrial Machinery/Components
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLNC Miscellaneous
- NVAX Health Care
- Exchange
- FLNC Nasdaq
- NVAX Nasdaq
- Market Cap
- FLNC 802.6M
- NVAX 1.3B
- IPO Year
- FLNC 2021
- NVAX 1995
- Fundamental
- Price
- FLNC $8.17
- NVAX $6.84
- Analyst Decision
- FLNC Buy
- NVAX Buy
- Analyst Count
- FLNC 18
- NVAX 5
- Target Price
- FLNC $8.58
- NVAX $16.60
- AVG Volume (30 Days)
- FLNC 6.2M
- NVAX 4.9M
- Earning Date
- FLNC 08-06-2025
- NVAX 08-07-2025
- Dividend Yield
- FLNC N/A
- NVAX N/A
- EPS Growth
- FLNC N/A
- NVAX N/A
- EPS
- FLNC N/A
- NVAX 2.97
- Revenue
- FLNC $2,329,871,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- FLNC $3.61
- NVAX $56.85
- Revenue Next Year
- FLNC $25.79
- NVAX N/A
- P/E Ratio
- FLNC N/A
- NVAX $2.30
- Revenue Growth
- FLNC 6.08
- NVAX 25.92
- 52 Week Low
- FLNC $3.46
- NVAX $5.01
- 52 Week High
- FLNC $24.00
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- FLNC 68.98
- NVAX 51.12
- Support Level
- FLNC $6.06
- NVAX $6.54
- Resistance Level
- FLNC $8.92
- NVAX $7.20
- Average True Range (ATR)
- FLNC 0.59
- NVAX 0.28
- MACD
- FLNC 0.18
- NVAX 0.06
- Stochastic Oscillator
- FLNC 78.68
- NVAX 66.36
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.